

ABSTRACT

This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of
5 said compounds for the treatment or prevention of diseases or conditions responding to SSTR1 active compounds. Moreover, the invention concerns methods of targeting a tissue bearing SSTR1s either for tissue imaging or as carriers for drugs to be transported to said tissue.